Back to top

Analyst Blog

Last week, several biotech companies attended the J.P. Morgan Annual Healthcare Conference where pipeline updates, strategic goals and guidance for 2014 were presented. Many companies also presented preliminary results.  

Celgene (CELG - Analyst Report) Impresses with Prelim Results & Outlook: Celgene expects to deliver 2013 earnings of $5.96 per share, well above expectations. Total net product sales are expected to come in at $6.4 billion, up 18%. 2014 guidance also surpassed expectations.

Moreover, the company’s long-term outlook looks good with Celgene raising its product sales targets as well as earnings outlook for 2015 and 2017.

Jazz (JAZZ - Analyst Report) Hits 52-Week High: Jazz hit a 52-week high last week after it presented a strong outlook at the J.P. Morgan conference and announced the acquisition of global development, manufacturing and commercial rights to ADX-N05 from Aerial BioPharma. ADX-N05 is being developed for the treatment of excessive daytime sleepiness in patients suffering from narcolepsy.

Meanwhile, Jazz expects to cross the $1 billion revenue mark in 2014, driven by continued growth of existing products and new product launches.

Sarepta (SRPT - Analyst Report) Spikes on Study Data: Sarepta's shares jumped 40.1% on 120-week data from a phase IIb study being conducted on its experimental drug, eteplirsen, for Duchenne muscular dystrophy. This is the long-term extension phase of the study which had met its primary endpoint at week 48. Patients on the experimental drug continued to show stability in walking ability. Investors are now eagerly awaiting an update on the company’s plans for phase III development.

Alnylam (ALNY - Analyst Report) Continues to Attract Big Pharma: Big pharma companies continue to show a lot of interest in Alnylam – Sanofi expanded its agreement with the company for the development of rare genetic diseases. Genzyme, Sanofi’s subsidiary, will acquire a 12% stake in Alnylam through a $700 million investment. This deal validates Alnylam’s technology, ensures continued pipeline progress and provides the company with a pile of cash. Alnylam’s shares shot up 40.9% on the news.

Regeneron’s (REGN - Analyst Report) Eylea Worth Keeping an Eye On: Regeneron was also there at the J.P. Morgan conference where the company said that it expects Eylea’s fourth quarter sales to be about $400 million and $1.4 billion in 2013. Importantly, Eylea continues to represent significant growth potential in the form of additional indications and continued uptake for approved indications. Shares were up 11.8%.

Regeneron has also signed up with health care giant, Bayer, for the joint development of a PDGFR (Platelet Derived Growth Factor Receptor Beta) beta antibody. The companies intend to explore the possibility of combining this antibody with Eylea for the treatment of wet age-related macular degeneration.

Regeneron will split development costs with Bayer and will get an upfront payment of $25.5 million as well as milestone payments. Moreover, U.S. commercialization rights remain exclusively with Regeneron. Will the companies be able to re-create the success they have enjoyed with Eylea?  Given their successful track record with Eylea, confidence levels remain high.
 

Company Last Week Last 6 Months
AMGN 0.98% 15.21%
BIIB -0.61% 32.15%
GILD  4.71% 35.76%
CELG -1.63% 22.28%
REGN 6.42% 8.34%
ALXN 3.33% 28.54%
^BTK 3.51% 18.66%

Other Developments:

Gilead (GILD - Analyst Report) Scores EU Approval for Sovaldi: The EU approved Gilead’s hepatitis C virus (HCV) infection treatment, Sovaldi. Sovaldi’s approval, while expected, is an important event for Gilead as well as HCV patients in the EU who have postponed treatment as they await the launch of a better therapy. Sovaldi basically represents a new HCV treatment paradigm – high cure rates, a short treatment period and reduction/elimination of the need for interferon injections. The EU market is huge with about 9 million people carrying the infection. Sovaldi, a potential blockbuster product, is already approved in the U.S.

Alexion (ALXN - Analyst Report) Teams Up with Moderna: Alexion is teaming up with Moderna Therapeutics for the discovery and development of messenger RNA Therapeutics (mRNA) for the treatment of rare diseases, Alexion’s focus area. The mRNA Therapeutics platform could help fasten the development and manufacture of treatments for several rare diseases that cannot be treated with existing technologies.

ARIAD (ARIA - Snapshot Report) Back with Iclusig: ARIAD has re-launched Iclusig in the U.S. after the product was temporarily suspended a few months back due to safety issues. Iclusig is back with a revised label, a boxed warning and a REMS plan. The question remains whether Iclusig will be able to bounce back and pick up where it left. Sales in the third quarter of 2013 were $16.7 million.

Will Provenge Sales Continue to Improve? Dendreon (DNDN - Analyst Report) reported a sequential improvement in Provenge sales and saw its shares jump 9%. But will this be enough to regain confidence in the product’s prospects? Remember, the prostate cancer market has several strong treatments like Zytiga and Xtandi.

The Week So Far:

Amarin’s (AMRN - Snapshot Report) Woes Continue: Amarin’s shares lost 23.8% on news that the Special Protocol Assessment for the ANCHOR study for Vascepa will not be re-instated.

Orphan Drug Status for Alexion Drug: The FDA granted orphan drug status to Soliris for the prevention of delayed graft function (DGF) in renal transplant patients.

BioMarin (BMRN - Analyst Report) Strikes Deal for Pre-Clinical Compounds: BioMarin is making an upfront payment of $2 million to Repligen Corp. for the latter’s histone deacetylase inhibitor (HDACi) library and related intellectual property.

Later this week, Cubist (CBST - Analyst Report) will be reporting fourth quarter results. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%
STRATTEC SE… STRT 80.24 +3.00%